 |  |  |  | Related Healthscout Videos |  |
|
Page: << Prev | 1 | 2 | 3 Alemtuzumab reduced by 74 percent the risk of MS relapse, the researchers reported in the Oct. 23 issue of the New England Journal of Medicine.
"The ability of an MS drug to promote brain repair is unprecedented," Alasdair Coles, of Cambridge University in England, and one of the study's leaders, told the AFP news service. "We are witnessing a drug which, if given early enough, might effectively stop the advancement of the disease and also restore lost function by promoting repair of the damaged brain tissue."
However, in an accompanying journal editorial, Dr. Stephen L. Hauser, a neurologist at the University of California, San Francisco, said the "toxic effects associated with alemtuzumab considerably dampen any enthusiasm for its routine use in patients with multiple sclerosis until more is known about its long-term safety and sustained efficacy."
Text Continues Below

More information
The U.S. National Institute of Neurological Disorders and Stroke has more about multiple sclerosis.
Page: << Prev | 1 | 2 | 3
-- Robert Preidt
|